Page 6 - Memory Disorders Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Memory disorders program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Memory Disorders Program Today - Breaking & Trending Today

Neuronascent Releases Positive Topline Phase 1a Safety Results of NNI-362 for Alzheimer's Disease

Neuronascent Releases Positive Topline Phase 1a Safety Results of NNI-362 for Alzheimer's Disease
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Johnf Kouten , Judith Kelleher Andersson , R Scott Turner , Neuronascent Inc , Georgetown University , Memory Disorders Program , National Institutes Of Health , Prnewswire Neuronascent Inc , National Institute On Aging , National Institute , National Institutes , Maximum Tolerated Dose , Neuronascent Scientific Advisory , Clinical Trials , Securities Litigation Reform Act ,

Neuronascent Releases Positive Topline Phase 1a Safety Results of NNI-362 for Alzheimer's Disease

Neuronascent Releases Positive Topline Phase 1a Safety Results of NNI-362 for Alzheimer's Disease
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Johnf Kouten , Judith Kelleher Andersson , R Scott Turner , Neuronascent Inc , Georgetown University , Memory Disorders Program , National Institutes Of Health , Prnewswire Neuronascent Inc , National Institute On Aging , National Institute , National Institutes , Maximum Tolerated Dose , Neuronascent Scientific Advisory , Clinical Trials , Securities Litigation Reform Act ,

Neuronascent Announces Publication of Pre-clinical Results of Alzheimer's Disease Clinical Candidate, NNI-362 in SCR&T Journal

Published: Jan 20, 2021
CLARKSVILLE, Md., Jan. 20, 2021 (GLOBE NEWSWIRE)
Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced the publication of results of their novel pharmacotherapy: NNI-362 to allosterically stimulate neural regeneration in human cultures and
in vivo models of aging and disease. This small molecule therapy is presently in Phase 1 clinical trial for mild to moderate Alzheimer’s disease (AD), which is supported by a NIA R01 grant in healthy aged volunteers.
The short report in the Stem Cell Research & Therapy journal https://doi.org/10.1186/s13287-020-02126-3 entitled “Novel pharmacotherapy: NNI-362, an allosteric p70S6 kinase stimulator, reverses cognitive and neural regenerative deficits in models of aging and disease”, describes the phenotypic screen used by Neuronascent to discover NNI-362 and details the ....

Judith Kelleher Andersson , R Scott Turner , Neuronascent Inc , Stem Cell Research Therapy , Memory Disorders Program At Georgetown University , Stem Cell Research , Memory Disorders Program , Georgetown University , Scientific Advisory Board , Neuronascent Announces Publication Of Pre Clinical Results Alzheimers Disease Candidate , Nni 362 In Scr Ampt Journal , ஜூடித் கெலெஹர் ஆண்டர்சன் , ர் ஸ்காட் டர்னர் , தண்டு செல் ஆராய்ச்சி சிகிச்சை , நினைவு கோளாறுகள் ப்ரோக்ர்யாம் இல் ஜார்ஜ்டவுன் பல்கலைக்கழகம் , தண்டு செல் ஆராய்ச்சி , நினைவு கோளாறுகள் ப்ரோக்ர்யாம் , ஜார்ஜ்டவுன் பல்கலைக்கழகம் ,